Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 18, 2017; 88 (16 Supplement) April 27, 2017

Therapeutic Effect of KPT-350 in a Preclinical Model of Duchenne Muscular Dystrophy (S42.003)

Devin Gibbs, Rylie Hightower, Christopher Lee, Janelle Spinazzola, Lillian Mead, Jeffrey Widrick, Sharon Tamir, Shelton Cochran, Yosef Landesman, Louis Kunkel, Matthew Alexander
First published April 17, 2017,
Devin Gibbs
1Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rylie Hightower
2University of Alabama at Birmingham Graduate School of Biomedical Sciences Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Lee
1Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janelle Spinazzola
1Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lillian Mead
1Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Widrick
1Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Tamir
3Karyopharm Therapeutics Newton MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shelton Cochran
3Karyopharm Therapeutics Newton MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yosef Landesman
3Karyopharm Therapeutics Newton MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Kunkel
1Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Alexander
4Department of Pediatrics, Division of Neurology at Children’s of Alabama and the University of Alabama at Birmingham Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Therapeutic Effect of KPT-350 in a Preclinical Model of Duchenne Muscular Dystrophy (S42.003)
Devin Gibbs, Rylie Hightower, Christopher Lee, Janelle Spinazzola, Lillian Mead, Jeffrey Widrick, Sharon Tamir, Shelton Cochran, Yosef Landesman, Louis Kunkel, Matthew Alexander
Neurology Apr 2017, 88 (16 Supplement) S42.003;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: This study evaluated the effectiveness of the Selective Inhibitor of Nuclear Export (SINE) compound KPT-350 in a zebrafish model of Duchenne muscular dystrophy (DMD).

Background: DMD is an X-linked disorder that afflicts approximately 1:5000 live male births, making it the most common form of muscular dystrophy worldwide. The nuclear export protein XPO1/CRM1 is a promising target for the treatment of neurological disorders with inflammatory pathology such as DMD. IκBα, a protein cargo of XPO1, inhibits pro-inflammatory transcription factor NF-κB activity by preventing its transcription. KPT-350 is a potent, orally available, slowly reversible, small molecule inhibitor of XPO1, and KPT-350 administration increases the amount of endogenous IKB, thus inhibiting NFKB’s function.

Design/Methods: In order to assess the short term effect of KPT-350 treatment on dystrophic disease phenotype and muscle architecture, sapje zebrafish (a severe model of DMD) embryos were treated from 1 to 5 days post-fertilization (dpf) with vehicle, 1.25 μM KPT-350, 2.5 μM KPT-350, or 2.5 μM aminophylline (positive control). In order to assess the effects of long-term KPT-350 treatment on survivability, sapje zebrafish were treated 3x/week for 24 hrs/dose with vehicle, 0.1 μM KPT-350, 1.0 μM KPT-350, or 2.5 μM aminophylline for 21 dpf.

Results: In short-term treatment studies, KPT-350-treated sapje zebrafish showed significant prevention of the muscle degeneration pathology associated with dystrophin deficiency and improved overall muscle architecture as determined by histological analysis of myosin heavy chains. With long term treatment, KPT-350 extended the lifespan of the sapje zebrafish, with a significant number of KPT-350-treated sapje mutants surviving well past 10 dpf, and reduced overall dystrophic pathology.

Conclusions: KPT-350 is an IND-ready compound and our studies demonstrate that it can improve the symptoms associated with muscular dystrophy and is a promising small molecule compound for the treatment of dystrophin-deficiency.

Study Supported by: Karyopharm Therapeutics

Disclosure: Dr. Gibbs has nothing to disclose. Dr. Hightower has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Spinazzola has nothing to disclose. Dr. Mead has nothing to disclose. Dr. Widrick has nothing to disclose. Dr. Tamir has received personal compensation for activities with Karyopharm Therapeutics Inc., as an employee. Dr. Cochran has received personal compensation for activities with Karyopharm Therapeutics Inc. as an employee. Dr. Landesman has received personal compensation for activities with Karyopharm as an employee. Dr. Kunkel has received personal compensation for activities with Summit, Sarepta, and Clartitas as an advisory board member and consultant. Dr. Kunkel has received research support from Pfizer. Dr. Alexander has nothing to disclose.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise